Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...
The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...
Opinion
A Medical Breakthrough Saved Millions of Lives During COVID. Why Are We Turning Our Backs on It Now?
By Clay Alspach The U.S. government is turning its back on a medical breakthrough that has saved millions of lives, halting $500 million in federal funding to develop new mRNA […] ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...
Researchers in the TB Alliance informed the Union Conference on Lung Health in Copenhagen that Sorbequiline, a new antibiotic ...
Merck on Wednesday said the Phase 3 study of the once-daily, two-drug single-tablet regimen met the success criterion for its primary efficacy hypothesis, showing non-inferiority to the three-drug ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback